Final results of patients with metastatic renal cell carcinoma treated with MGN1601 in the ASET study.Viktor Grünwald, Burghardt Wittig, Steffen Weikert et al.|Journal of Clinical Oncology|2014Cited by 7
ASET study: Long-term follow-up data of patients with metastatic renal cell carcinoma treated with MGN1601.Viktor Gruenwald, Burghardt Wittig, Manuel Schmidt et al.|Journal of Clinical Oncology|2014Cited by 4
Identification of biomarkers for overall survival of patients with metastatic renal cell carcinoma treated with MGN1601.Viktor Grünwald, Burghardt Wittig, Steffen Weikert et al.|Journal of Clinical Oncology|2013Cited by 1
New safety and efficacy data of the ongoing phase I/II study (ASET Study) with an allogeneic tumor vaccine and adjuvant in patients with metastatic renal cell carcinoma.Viktor Grünwald, Burghardt Wittig, Steffen Weikert et al.|Journal of Clinical Oncology|2012Cited by 1
Efficacy and safety of cancer vaccine with 4-fold gene-modified allogeneic tumor cells: Results of the phase I/II ASET study in patients with advanced renal cell carcinoma.Steffen Weikert, Burghardt Wittig, Viktor Grünwald et al.|Journal of Clinical Oncology|2012Cited by 1